Daiwa Securities Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-498
Closed 1385
2023
Q3
$0 Hold
498
﹤0.01% 1331
2023
Q2
$1K Hold
498
﹤0.01% 1296
2023
Q1
$1K Hold
498
﹤0.01% 1280
2022
Q4
$2K Hold
498
﹤0.01% 1237
2022
Q3
$2K Hold
498
﹤0.01% 1247
2022
Q2
$2K Hold
498
﹤0.01% 1254
2022
Q1
$3K Hold
498
﹤0.01% 1229
2021
Q4
$4K Hold
498
﹤0.01% 1229
2021
Q3
$4K Buy
498
+232
+87% +$2.29K ﹤0.01% 1200
2021
Q2
$3K Hold
266
﹤0.01% 1119
2021
Q1
$3K Hold
266
﹤0.01% 1118
2020
Q4
$4K Sell
266
-536
-67% -$6.28K ﹤0.01% 1072
2020
Q3
$8K Buy
802
+148
+23% +$1.6K ﹤0.01% 1059
2020
Q2
$4K Hold
654
﹤0.01% 1127
2020
Q1
$4K Hold
654
﹤0.01% 1123
2019
Q4
$5K Sell
654
-72
-10% -$662 ﹤0.01% 1106
2019
Q3
$7K Hold
726
﹤0.01% 1055
2019
Q2
$8K Buy
726
+77
+12% +$819 ﹤0.01% 1067
2019
Q1
$6K Buy
649
+182
+39% +$1.86K ﹤0.01% 1069
2018
Q4
$5K Hold
467
﹤0.01% 1058
2018
Q3
$8K Hold
467
﹤0.01% 1058
2018
Q2
$7K Hold
467
﹤0.01% 1074
2018
Q1
$9K Buy
+467
New +$9.98K ﹤0.01% 1037

Other funds holding SGMO

Daiwa Securities Group's SGMO Position: Q4 2023 in Review

Daiwa Securities Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 498 shares.

Daiwa Securities Group first reported a position in SGMO in Q1 2018 and held it in 23 quarters. The position peaked at $9K in Q1 2018. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Daiwa Securities Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 498 SANGAMO THERAPEUTICS INC shares in Q4 2023.
  • Daiwa Securities Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 23 quarters.
  • Daiwa Securities Group's SANGAMO THERAPEUTICS INC position peaked at $9K in Q1 2018.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.